Testing NPI-001 for preserving vision in Usher syndrome
Part of Brain & nervous system, Ear, nose & throat, Eyes & vision, Genetic & congenital clinical trials.
This trial tests an oral medication (NPI-001) to see if it can preserve the light-sensing cells in the retina for people with retinitis pigmentosa caused by Usher syndrome. It lasts 24 months and requires several eye exams to monitor changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of retinitis pigmentosa caused by Usher syndrome.
- You must be able to read and agree to the study rules and visit schedule.
- Your eye exam must show a certain amount of healthy retina (EZ width at least 500 microns) in both eyes.
- You must have at least 20 measurable points on a special vision test (MAIA microperimetry) in at least one eye both times it's tested.
- You cannot have other serious eye diseases (like glaucoma or cataract blocking the view) or unstable fixation during the test.
- You cannot have taken N-acetylcysteine supplements in the last 30 days or be on any other experimental drug in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called NPI-001 (N-acetylcysteine) to see if it can help protect the light-sensing cells in the eyes of people with Usher syndrome, a genetic condition that causes vision and hearing loss. The study lasts 24 months and measures how well the retina stays healthy.
This study follows people with Usher syndrome type 1B over time to learn how vision loss progresses. It also tests new ways to measure functional vision, which may help design future treatments.
This study tests a new eye injection containing pitavastatin, a drug normally used for cholesterol, wrapped in tiny particles. The goal is to see if it is safe and if it can help slow vision loss in people with retinitis pigmentosa.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This trial tests a gene therapy injection (UGX202) for people with advanced retinitis pigmentosa (RP) who have very poor vision. It aims to see if the treatment can help improve or preserve sight.
This trial tests a new gene therapy injection (ZM-02) that uses light-sensitive proteins to help restore vision in people with advanced retinitis pigmentosa. It’s designed to see if the treatment is safe and can improve vision.
Hear when a new Usher Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.